HEALTH: Requests the Louisiana Department of Health to study the effects of gender affirming therapy on mental health
House Resolution 290 requests the Louisiana Department of Health to study whether medications used in gender-affirming hormone therapy are correlated with psychosis and related psychiatric conditions in people 26 years of age and younger. The resolution specifically calls for review of peer-reviewed medical literature, adverse event data, and consultation with a range of medical professionals, including behavioral health specialists, endocrinologists, psychiatrists, therapists, pediatric specialists, and pharmacologists.
The study is also directed to consider possible recommendations on informed consent standards, patient screening, mental health evaluations, monitoring protocols, and areas where additional research may be needed. LDH would be required to submit a written report, and any recommendations, to the House Committee on Health and Welfare by February 1, 2027. As a resolution, it does not itself change clinical practice or create new regulatory requirements, but it would formally direct a state agency to examine the issue and report back to the legislature.
HR 290 would not amend the Louisiana Revised Statutes or directly regulate gender-affirming care, mental health treatment, or prescription practices. Its legal effect is limited to urging and requesting the Louisiana Department of Health to conduct or coordinate a study and to deliver findings to the legislature, which could later inform future policy, oversight, or legislation affecting minors and young adults receiving gender-affirming hormone therapy.
Based on the bill text and its committee posture, the measure appears to be framed as a fact-finding resolution rather than an immediate policy change. There is no recorded vote or committee transcript in the provided materials, and the bill was pending in House Health and Welfare, so the available record does not show formal support or opposition. The language emphasizes scientific review, consultation, and reporting, suggesting proponents are presenting it as a health and research inquiry.
The main point of contention is the bill’s focus on gender-affirming hormone therapy and its stated interest in possible links to psychosis, schizophrenia-spectrum disorders, severe mood disorders, dissociative conditions, and suicidal ideation in people 26 and under. Supporters would likely characterize the resolution as a public-health study intended to improve informed consent and monitoring, while critics may view it as targeting transgender healthcare or relying on disputed assumptions about mental health risks. The inclusion of a broad range of psychiatric outcomes and the emphasis on medications such as puberty blockers, estrogen, testosterone, and androgen blockers are likely to be the central areas of debate.